Live feed07:30:00·6dPRReleasevia QuantisnowBiohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA NephropathyByQuantisnow·Wall Street's wire, on your screen.BHVN· Biohaven Ltd.Health Care
